Autologous Platelet Rich Plasma (PRP) Intra Ovarian Infusion in Perimenopausal Women
Trial statusRecruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexFemale
Age40-50
SponsorGenesis Athens Clinic
About this trial
Autologous PRP intra ovarian infusion may improve ovarian response and women's hormonal profile and may promote folliculogenesis in perimenopausal women.
Eligibility criteria
Qualifiers
Women ≥40 years of age, presenting with cycle irregularities while fulfilling at least one of the respective two criteria: more than seven days difference in menstrual cycle duration between two consecutive cycles OR, presence of a menstrual cycle duration over sixty days and progressive elevation of FSH levels.
Discontinuation of any complementary/adjuvant treatment including hormone replacement, acupuncture, and botanotherapy, for at least three months prior to recruitment.
Willing to comply with study requirements
Disqualifiers
Any pathological disorder related to reproductive system anatomy
Amenorrhea
Endometriosis
Adenomyosis
Trial design
Treatments tested in this trial
- Autologous Platelet Rich Plasma (PRP) intra ovarian infusion
- Placebo: Autologous Platelet Free Plasma (PFP) intra ovarian infusion
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Genesis Athens Clinic
Lead sponsor
National and Kapodistrian University of Athens
Collaborator
Source ClinicalTrials.gov